Stock listing

Sagimet Biosciences Inc. - Series A

Selected listing: 0O2 · TRADEGATE · EUR · DE

Sagimet Biosciences Inc. - Series A (Tradegate:0O2), Health Technology. Latest release Oct 1, 2026: Sagimet Biosciences Announces Closing of Underwritten…

0O2:TRADEGATEEURDEUpdated October 2, 2026

Ticker: Tradegate:0O2
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Tradegate
Currency: EUR

Latest news from Sagimet Biosciences Inc. - Series A

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

October 1, 2026

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

September 30, 2026

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

September 30, 2026

Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026

September 28, 2026

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

August 25, 2026

All Sagimet Biosciences Inc. - Series A news →

Research Sagimet Biosciences Inc. - Series A

Sagimet Biosciences Inc. - Series A company profile

View the public company page for Sagimet Biosciences Inc. - Series A on 6ix.

Sagimet Biosciences Inc. - Series A news

Read company news and market updates connected to Sagimet Biosciences Inc. - Series A.

Sagimet Biosciences Inc. - Series A investor events

Find investor webinars, events, and replay context for Sagimet Biosciences Inc. - Series A.